Encompass Health Corp (EHC) - 10-K Summary
Business Context and Reporting Period
Company: Encompass Health Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Encompass Health is the nation's largest owner and operator of inpatient rehabilitation hospitals (IRFs). As of December 31, 2024, the company operated 166 hospitals across 38 states and Puerto Rico, with significant concentrations in Florida and Texas. The company treats patients recovering from strokes, hip fractures, and neurological conditions, with 91% of patients admitted from acute-care hospitals.
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 | Change |
|---|---|---|---|
| Net Operating Revenues | $5,373.2 | $4,801.2 | +11.9% |
| Net Income (Total) | $596.6 | $463.0 | +28.9% |
| Net Income Attributable to Encompass Health | $455.7 | $352.0 | +29.5% |
| Diluted EPS (Attributable to Encompass Health) | $4.46 | $3.47 | +28.5% |
| Adjusted EBITDA | $1,103.7 | $971.1 | +13.7% |
| Operating Cash Flow | $1,002.8 | $850.8 | +17.9% |
| Long-Term Debt (Total) | $2,497.8 | $2,712.6 | -7.9% |
| Cash and Cash Equivalents | $85.4 | $69.1 | +23.6% |
| Revolving Credit Facility Availability | $944.0 | $1,000.0 | N/A |
Operational Metrics:
- Discharges: 248,498 (2024) vs. 229,480 (2023), an increase of 8.3%.
- Net Patient Revenue per Discharge: $21,048 (2024) vs. $20,454 (2023).
- Occupancy Rate: 74.6% (2024) vs. 72.1% (2023).
- Licensed Beds: 11,094 (2024) vs. 10,778 (2023).
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by volume growth (5.6% same-store discharge increase) and favorable pricing. Outpatient and other revenue increased 32.9% due to higher provider tax revenues.
- Profitability: Net income attributable to Encompass Health rose 29.5%. Operating expenses as a percentage of revenue decreased to 83.9% from 84.8% in 2023, aided by volume leverage and lower revenue reserves for bad debt.
- Debt Reduction: The company redeemed $250 million of its 5.75% Senior Notes due 2025 in August and November 2024, reducing total debt and interest expense.
- Impairment Charge: Recorded a $10.4 million impairment charge in Q1 2024 related to the closure of a joint venture hospital in Eau Claire, Wisconsin, following the closure of the partner acute-care hospital.
- Capital Expenditures: Increased to approximately $643 million in 2024 (from $583 million in 2023) to fund de novo projects and bed additions.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Growth Targets: The company targets adding 6 to 10 new hospitals and 80 to 120 beds annually. Several new facilities opened in 2024, with more scheduled for 2025.
- Capital Allocation: Maintains a flexible capital structure with no significant debt maturities until 2028. Plans to continue returning capital via dividends (increased to $0.17/share quarterly) and share repurchases ($489 million remaining authorization).
- 2025 CapEx: Expected to spend $740 million to $770 million on capital expenditures.
Key Risks and Contingencies:
- Reimbursement Risk: Approximately 82% of revenue comes from Medicare and Medicare Advantage. The company faces risks from CMS audits, the "60% Rule" compliance, and potential payment reductions. The 2025 IRF Rule is expected to result in a net 3.3% increase in Medicare payment rates.
- Regulatory Audits: The company is subject to various audit programs (RAC, UPIC, TPE). As of Dec 31, 2024, approximately $41 million in denied claims were under review or audit. The company recorded a $21.9 million reserve in Q4 2023 for uncollectible amounts related to prior appeals.
- Staffing: Labor shortages and wage inflation remain challenges, though contract labor usage decreased slightly in 2024.
- Cybersecurity: A February 2024 incident at Change Healthcare (a claims processor) temporarily disrupted claim submissions but did not materially affect financial results.
Investor Verification Checklist
- Medicare Audit Exposure: Verify the status of the $41 million in denied claims under review and the potential impact of the IRF Review Choice Demonstration (RCD) in Alabama on future collections.
- Debt Covenants: Confirm continued compliance with the 4.50x leverage ratio and 3.0x interest coverage ratio covenants under the credit agreement.
- Joint Venture Performance: Monitor the profitability of new joint ventures (e.g., Piedmont in Georgia) and the impact of partner acute-care hospital closures on referral volumes.
- Payor Mix Shift: Track the increasing percentage of Medicare Advantage revenue (16.8% in 2024) and its impact on net reimbursement rates compared to traditional Medicare.
- Capital Expenditure Execution: Assess the timeline and cost of the $410 million in projects under construction and the ability to fund the $740-$770 million 2025 budget.